scorecardresearch
Add as a preferred source on Google
Friday, April 3, 2026
TopicDrug regulation in India

Topic: Drug regulation in India

Antibiotics launched in India will soon need CDSCO nod as drug resistance emerges as silent killer

In 2019, bacterial antimicrobial resistance killed between 3 lakh and 10.4 lakh people in India, according to a Lancet report.

Govt approves 50% price rise for 8 essential drugs after manufacturers say production is ‘unviable’

Asthma, glaucoma, thalassemia, tuberculosis, and mental health patients require the drugs in question.

Health ministry bans FDCs every few years. Ask how they enter the market in the first place

The medical rationale behind fixed-dose combination drugs soon gave into commercial interests that cared little for the health of patients. Government's only response has been to keep issuing ban orders since 1983.

Govt panel urges regulator to approve import of American drug for diabetes, obesity

Lilly's Mounjaro is a popular choice for weight loss. Mounjaro is expected to launch in India in India in 2025.

Drug regulator gives conditional nod for sale of 5 FDCs, seeks efficacy & safety data for 3 of them

Popular brands using combinations under the scanner include D Cold Total and Dolo Cold. The five FDCs are part of 344 drug combinations that the government had first banned in 2016.

Jailed in Punjab, acquitted in Bengal—How judiciary handled drug law violations

In 'Truth Pill: The Myth of Drug Regulation in India', authors Dinesh S. Thakur and Prashant Reddy T. expose the faulty drug regulation in India.

‘Feeding cough syrup seems like Russian roulette’—new book exposes drug regulation in India

Dinesh S. Thakur and Prashant Reddy tapped into the nitty gritty of drug regulation, cough syrups and medicines in India at the launch of their book ‘Truth Pill’ in Delhi.

On Camera

Pam Bondi’s firing is good news. Now, US Senate must stand up for DOJ

Bondi’s missteps hastened her exit, but her departure offers a reset. The Senate must not rubber-stamp Trump’s pick and should demand an attorney general committed to DOJ independence.

SEBI proposes return of open market share buybacks to support stocks

Regulator seeks feedback on allowing firms to repurchase shares via exchanges after tax changes, as markets reel from war-led selloff and foreign outflows.

India commissions its third nuclear-powered ballistic missile submarine—INS Aridhaman

INS Arihant was first vessel under SSBN project and was quietly commissioned in 2016. The second indigenous SSBN, INS Arighat, was commissioned in August 2024.

Gulf war exposed India’s fragilities. It’s time for navel-gazing, in the national interest

It’s easy to understand why the government can’t speak the hard truth. When this war ends, as all wars do, India’s interests will lie with both the winner and the loser.